MedicaidPrior AuthMedium impact
Istodax (romidepsin) (New)
Humana·LA · Oncology, Hematology·Medicaid
Effective date
Mar 1, 2026
We identified it
Jun 24, 2026
Summary
New prior authorization policy established for Istodax (romidepsin) for Louisiana Medicaid patients with cutaneous T-cell lymphoma. Prior authorization is required for all romidepsin products, whether used as primary therapy or after one prior treatment, with specific exclusions for patients who experienced disease progression on romidepsin.
Action Required
Before March 1, 2026: Billing team must update prior authorization requirements for all Istodax/romidepsin products for Louisiana Medicaid patients. Ensure providers document that treatment is for cutaneous T-cell lymphoma and meets criteria for either primary biologic systemic therapy OR patient has received at least one prior therapy. Verify patients have not experienced disease progression while on romidepsin. Submit prior authorization requests through www.humana.com/PAL for medical billing. Claims without prior authorization will be denied.